Prophylactic and/or therapeutic agent for metabolic syndrome

Abstract

Disclosed are: a method for screening a substance for treating metabolic syndrome that develops visceral obesity and abnormal lipid metabolism; and a composition for preventing and / or treating the syndrome. The screening method comprises: (1) an extraction step of extracting a total RNA fraction from a skeletal muscle collected from each of non-human mammals that constitute a test substance-administered group to which a predetermined amount of the test substance has been administered for a predetermined period and each of non-human mammals that constitute a test substance-unadministered group to which the test substance has not been administered; (2) a quantification step of quantifying the expression quantity of mRNA contained in the total RNA fraction extracted in the extraction step and encoding a sugar transporter gene by a specific method; and (3) a step of comparing and analyzing the quantity of the test substance ingested, the body weight gain, and the expression quantity of RNA encoding the sugar transporter gene during the predetermined period between the non-human mammals that constitute the test substance-administered group and the non-human mammals that constitute the test substance-unadministered group to thereby determine the effect of the test substance on the metabolic syndrome.

Description

technical field

[0001] The present invention relates to a prophylactic and / or therapeutic agent for metabolic syndrome containing citrus extracts from the Satsuma region as an active ingredient, a pharmaceutical preparation for the prophylaxis and / or treatment of metabolic syndrome containing the above extract, and a drug for metabolic syndrome Functional food and health food for the prevention of symptoms. Background technique

[0002] The increase in symptoms such as hyperglycemia, hypertension, and lipid abnormalities caused by obesity is a common social problem in all countries in the world. In addition to the visceral fat type obesity caused by the hypertrophy of the built-in adipose tissue and leading to weight gain, the state of hyperglycemia, hypertension, and lipid abnormality combined with two or more states is called "metabolic syndrome (visceral fat syndrome)”, the National Cholesterol Education Program (NCEP) has published diagnostic criteria for this condition...

Examples

Embodiment 1

[0144] 1. Preparation of test substances, etc.

[0145] (1-1) The extraction method of the extract from the citrus peel of the mandarin orange region

[0146] The fruit of the flat mandarin orange is purchased from Daigimi, Okinawa Prefecture. The peel obtained from the flat orange fruit was dried in the sun for 3 days to obtain the flat orange dried peel. Satsuma tangerines are purchased from Ehime prefecture. In addition, the pericarp obtained from Satsuma citrus was dried in the sun for 3 days in the same manner to obtain dried satsuma citrus peel.

[0147] 40 L of methanol was added to 8 kg of these dried fruit peels to immerse them, and they were extracted at 4° C. for 14 days. Filtration was performed to obtain a crude extract, and the entire amount of the crude extract was concentrated using an evaporator. The concentrated solution was extracted by liquid-liquid distribution in 4 L of water / ethyl acetate (1 / 1), and then, the ethyl acetate phase was again extracted i...

Embodiment 2

[0163] 2. Measuring method of animal feed and gene expression level

[0164] (2-1) Feed for tested animals

[0165] CRF-1 (manufactured by Oriental Yeast Co., Ltd.) was purchased as a normal mouse feed (standard diet). As additives for the preparation of low-fat diet and high-fat diet, casein, tallow, β-cornstarch, α-cornstarch, dietary fiber, minerals and vitamins were purchased in the following amounts (w / w%) Add and use (both are manufactured by Oriental Yeast Co., ltd.). In addition, sucrose, L-cystine, choline bitartrate, and tert-butylhydroquinone were purchased and added to CRF-1 in the amounts (w / w%) shown in the table below for feeding (all were produced by Wako Pure Chemical Industry Co., Ltd. company manufacturing).

[0166] Table 1 is the food composition of the low-fat diet, the high-fat diet and the food added with SPE in Example 3. Each value represents weight % (w / w %). Components indicated by *1 were purchased from Wako Pure Chemical Industries. Sucrose,...

Embodiment 3

[0173] 3. Determination of the effect of SPE on obesity during high-fat diet intake

[0174] Animals used in the following examples were provided with a low fat diet (4% fat content) or a high fat diet (40% fat content). As a high-fat diet, three types of SPE-free diet, 1% SPE-added diet, and 1.5% SPE-added diet were prepared. In Example 3 below, the group taking a low-fat diet is represented as LFD intake group, the group taking SPE without high-fat diet is represented as HFD intake group, and the group taking 1% SPE plus high-fat diet is represented as HFD+1SPE intake In the group, the group that ingested 1.5% SPE was denoted as the HFD+1.5SPE ingestion group. In addition, in the following tables, they are represented as LFD, HFD, HFD+1SPE, and HFD+1.5SPE, respectively.

[0175] Regarding the animals used, C57BL / 6 mice at the age of 7 weeks after birth were purchased from CHARLES RIVER LABORATORIES JAPAN, INC. After being domesticated with standard food for 1 week, they we...

technical field

[0001] The present invention relates to a prophylactic and / or therapeutic agent for metabolic syndrome containing citrus extracts from the Satsuma region as an active ingredient, a pharmaceutical preparation for the prophylaxis and / or treatment of metabolic syndrome containing the above extract, and a drug for metabolic syndrome Functional food and health food for the prevention of symptoms. Background technique

[0002] The increase in symptoms such as hyperglycemia, hypertension, and lipid abnormalities caused by obesity is a common social problem in all countries in the world. In addition to the visceral fat type obesity caused by the hypertrophy of the built-in adipose tissue and leading to weight gain, the state of hyperglycemia, hypertension, and lipid abnormality combined with two or more states is called "metabolic syndrome (visceral fat syndrome)”, the National Cholesterol Education Program (NCEP) has published diagnostic criteria for this condition...

Examples

Embodiment 1

[0144] 1. Preparation of test substances, etc.

[0145] (1-1) The extraction method of the extract from the citrus peel of the mandarin orange region

[0146] The fruit of the flat mandarin orange is purchased from Daigimi, Okinawa Prefecture. The peel obtained from the flat orange fruit was dried in the sun for 3 days to obtain the flat orange dried peel. Satsuma tangerines are purchased from Ehime prefecture. In addition, the pericarp obtained from Satsuma citrus was dried in the sun for 3 days in the same manner to obtain dried satsuma citrus peel.

[0147] 40 L of methanol was added to 8 kg of these dried fruit peels to immerse them, and they were extracted at 4° C. for 14 days. Filtration was performed to obtain a crude extract, and the entire amount of the crude extract was concentrated using an evaporator. The concentrated solution was extracted by liquid-liquid distribution in 4 L of water / ethyl acetate (1 / 1), and then, the ethyl acetate phase was again extracted i...

Embodiment 2

[0163] 2. Measuring method of animal feed and gene expression level

[0164] (2-1) Feed for tested animals

[0165] CRF-1 (manufactured by Oriental Yeast Co., Ltd.) was purchased as a normal mouse feed (standard diet). As additives for the preparation of low-fat diet and high-fat diet, casein, tallow, β-cornstarch, α-cornstarch, dietary fiber, minerals and vitamins were purchased in the following amounts (w / w%) Add and use (both are manufactured by Oriental Yeast Co., ltd.). In addition, sucrose, L-cystine, choline bitartrate, and tert-butylhydroquinone were purchased and added to CRF-1 in the amounts (w / w%) shown in the table below for feeding (all were produced by Wako Pure Chemical Industry Co., Ltd. company manufacturing).

[0166] Table 1 is the food composition of the low-fat diet, the high-fat diet and the food added with SPE in Example 3. Each value represents weight % (w / w %). Components indicated by *1 were purchased from Wako Pure Chemical Industries. Sucrose,...

Embodiment 3

[0173] 3. Determination of the effect of SPE on obesity during high-fat diet intake

[0174] Animals used in the following examples were provided with a low fat diet (4% fat content) or a high fat diet (40% fat content). As a high-fat diet, three types of SPE-free diet, 1% SPE-added diet, and 1.5% SPE-added diet were prepared. In Example 3 below, the group taking a low-fat diet is represented as LFD intake group, the group taking SPE without high-fat diet is represented as HFD intake group, and the group taking 1% SPE plus high-fat diet is represented as HFD+1SPE intake In the group, the group that ingested 1.5% SPE was denoted as the HFD+1.5SPE ingestion group. In addition, in the following tables, they are represented as LFD, HFD, HFD+1SPE, and HFD+1.5SPE, respectively.

[0175] Regarding the animals used, C57BL / 6 mice at the age of 7 weeks after birth were purchased from CHARLES RIVER LABORATORIES JAPAN, INC. After being domesticated with standard food for 1 week, they we...

Images